NuGEN Announces Launch of WT-Ovation(TM) RNA Amplification System; Enables Analysis Across the Entire Transcriptome Without 3' Bias.
SAN CARLOS San Carlos (săn kär`lōs), residential city (1990 pop. 26,167), San Mateo co., W Calif.; inc. 1925. The chief manufactures are plastic products, hardware, and machine parts. , Calif. -- Built on NuGEN's Proprietary Ribo-SPIA(TM) Technology to Achieve Linear Amplification of mRNA
NuGEN Technologies Inc., a privately held company privately held company
A firm whose shares are held within a relatively small circle of owners and are not traded publicly. that develops and commercializes the new standard in nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. amplification and labeling systems, today announced the launch of the WT-Ovation(TM) RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic Amplification System amplification system Physiology A generic term for any group of proteins that function in coordinated sequences, forming positive feedback loops for expanding the response to a low intensity signal
polymerase chain reaction
Polymerase chain reaction (PCR) . This enables researchers to conduct gene studies even when only small amounts of RNA are obtainable.
"Current RNA amplification systems are limited because they rely on the 3' end of the RNA to initiate amplification. These 3'-biased methods only amplify mRNA with intact Poly-A," said Elizabeth Hutt, vice president of commercial operations at NuGEN. "WT-Ovation provides a revolutionary approach to RNA amplification. Whole Transcript Amplification effectively initiates the process from anywhere along the mRNA without the need for a Poly-A tail. For the first time, researchers can interrogate the full length of the transcripts regardless of the presence or absence of a Poly-A tail. For example, they can now effectively study splice variants, examine archived or degraded samples, investigate prokaryotic pro·kar·y·ote also pro·car·y·ote
An organism of the kingdom Monera (or Prokaryotae), comprising the bacteria and cyanobacteria, characterized by the absence of a distinct, membrane-bound nucleus or membrane-bound organelles, and by DNA that samples, and at the same time bank or archive amplification products of precious samples."
The WT-Ovation(TM) product is powered by the company's proprietary Ribo-SPIA(TM) technology, a patented linear amplification method that generates sensitive and high fidelity results. Pre-amplification produces cDNA in proportion to the amount of mRNA species in a sample, maintaining representation, and subsequently enhancing the sensitivity of QPCR QPCR Quantitative Polymerase Chain Reaction analyses. As with other Ovation(TM) products, WT-Ovation(TM) requires the same small input and delivers unparalleled yield, fidelity and representation in one day.
"WT-Ovation is a distinctly different amplification approach that delivers superior speed, performance and convenience to whole-transcript analysis," said Elizabeth Davila, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of NuGEN. "Studying messenger RNA mes·sen·ger RNA
See mRNA. populations across the entire transcriptome The transcriptome is the set of all messenger RNA (mRNA) molecules, or "transcripts", produced in one or a population of cells. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. is now a reality, and WT-Ovation provides an automation-friendly solution to researchers who have high throughput volumes."
For pricing and availability information for the WT-Ovation(TM) RNA Amplification System, please contact NuGEN Technologies at 888-654-6544 or firstname.lastname@example.org.
About NuGEN Technologies Inc.
NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA SPIA Single Premium Immediate Annuity
SPIA School of Public and International Affairs (Virginia Tech)
SPIA Standards Profile for Imagery Access
SPIA Small Payload Interface Adapter
SPIA Scanner Power Interface Assembly (TM) and Ribo-SPIA(TM) amplification and labeling system for DNA- and RNA-based applications form the foundation for a wide range of methods and products used by life scientists. The Ovation(TM) amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.
NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies Inc. All other marks are the property of their respective owners.
This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.